Pfizer bags approval for Neupogen biosimilar
Pfizer’s Neupogen biosimilar Nivestym has been approved by the US Food and Drug Administration and is expected to hit the market at a “significant discount” to its reference drug.
Read More
Tag: Neupogen
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
